enkephalin--leucine-2-alanine and binaltorphimine

enkephalin--leucine-2-alanine has been researched along with binaltorphimine* in 3 studies

Other Studies

3 other study(ies) available for enkephalin--leucine-2-alanine and binaltorphimine

ArticleYear
Involvement of mu1 and mu2 opioid receptor subtypes in tail-pinch feeding in rats.
    Physiology & behavior, 1993, Volume: 53, Issue:3

    Tail-pinch feeding (TPF) in rats is decreased following general (naltrexone, NTX) and mu (Cys2-Tyr3-Orn5-Pen7-amide, CTOP) opioid antagonists, but not following kappa (nor-binaltorphamine. Nor-BNI) or delta (naltrindole, NTI) opioid antagonists. Because multiple mu (mu1 and mu2) and delta (delta 1 and delta 2) opioid receptor subtypes have been characterized, the present study evaluated whether TPF was differentially altered following ICV administration of general (NTX), mu (beta-funaltrexamine, B-FNA), mu1 (naloxonazine, NAZ), kappa (Nor-BNI), delta 1 ([D-Ala2, Leu5, Cys6]-enkephalin, DALCE) and delta 2 (NTI) opioid antagonists. Like the reversible mu antagonist CTOP, the irreversible mu antagonist B-FNA significantly and dose-dependently (1-20 micrograms) reduced TPF by up to 28%. In contrast, whereas NAZ (50 micrograms) reduced TPF by 32%, this effect was highly variable and failed to achieve significance. Neither NTX (5-10 mg/kg, SC), Nor-BNI (20 micrograms), DALCE (40 micrograms) nor NTI (20 micrograms) significantly altered TPF, suggesting that kappa, delta 1 and delta 2 opioid receptor subtypes were not involved. Because no antagonist altered the duration of food contact during tail pinch, it appears that the opioid effect modulates ingestive rather than activational mechanisms. The reliable inhibition of TPF by B-FNA (mu1 and mu2), together with the variable effect of naloxonazine (mu1), appears to implicate both mu binding sites in this response.

    Topics: Animals; Arousal; Enkephalin, Leucine-2-Alanine; Feeding Behavior; Indoles; Male; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu

1993
Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity.
    Journal of medicinal chemistry, 1988, Volume: 31, Issue:4

    In an effort to develop selective antagonists for kappa opioid receptors, bivalent ligands that contain opioid antagonist pharmacophores derived from naltrexone or other morphinans were synthesized and tested on the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations. The minimum requirements for kappa selectivity are at least one free phenolic OH group and one N-cyclopropyl or N-ally substituent. Several compounds (3, 8, 10) with kappa selectivity as good as or better than norbinaltorphimine (nor-BNI, 2) were discovered. The structure-activity relationship revealed that the pyrrole ring functions strictly as a spacer and does not contribute to kappa selectivity. The pharmacologic data suggest that only one antagonist pharmacophore may be required for kappa selectivity and that the other morphinan portion of the molecule confers selectivity by interacting with a unique subsite proximal to the antagonist pharmacophore recognition locus.

    Topics: Animals; Chemical Phenomena; Chemistry; Cyclazocine; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Ethylketocyclazocine; Guinea Pigs; Male; Mice; Models, Molecular; Morphine; Muscle, Smooth; Naltrexone; Receptors, Opioid; Receptors, Opioid, kappa; Structure-Activity Relationship

1988
Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.
    Life sciences, 1987, Mar-30, Volume: 40, Issue:13

    The opioid antagonist activities of two bivalent ligands, BNI and nor-BNI, have been evaluated in smooth muscle preparations and in mice. Both ligands are highly potent and selective as kappa opioid receptor antagonists, with relatively feeble blocking activity at mu and delta opioid receptors. BNI and nor-BNI represent the first highly selective kappa opioid receptor antagonists and should be of great utility as molecular probes for identifying the interaction of agonist ligands with kappa opioid receptors in vitro and in vivo.

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Chemical Phenomena; Chemistry; Cyclazocine; Dynorphins; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Ethylketocyclazocine; Guinea Pigs; Male; Mice; Morphine; Naloxone; Naltrexone; Pyrrolidines; Rabbits; Receptors, Opioid; Receptors, Opioid, kappa

1987